* Says Cidara plans to commence a phase 2 Comparative
clinical trial of CD101 topical in VVC ( Radiant Study) in
mid-2016
The post BRIEF-Cidara says FDA granted Fast Track designation to antifungal product candidate appeared first on NASDAQ.
BRIEF-Cidara says FDA granted Fast Track designation to antifungal product candidate
